Crinetics Pharmaceuticals, Inc. (CRNX) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
4.12
+17% vs avg
5yr avg: 3.53
30Y Low2.5·High5.2
ROE
↑
-40.2%
↓+7% vs avg
5yr avg: -43.2%
30Y Low-134%·High-32%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CRNX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Crinetics Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.6B | $4.4B | $4.1B | $2.1B | $951M | $1.1B | $430M | $607M | $364M | — | — |
| Enterprise Value | $4.5B | $4.3B | $3.9B | $2.1B | $922M | $894M | $341M | $572M | $319M | — | — |
| P/E Ratio → | -8.78 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 591.48 | 568.91 | 3975.39 | 514.87 | 200.82 | 1012.96 | 6051.00 | 508.42 | 149.97 | — | — |
| P/B Ratio | 4.12 | 4.41 | 3.12 | 3.83 | 3.01 | 3.29 | 2.54 | 5.18 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CRNX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 562.03 | 3770.56 | 514.08 | 194.57 | 829.63 | 4796.45 | 479.29 | 131.45 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
CRNX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Crinetics Pharmaceuticals, Inc. earns an operating margin of -6714.8%. Operating margins have compressed from -5547.2% to -6714.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -40.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 35.5% | 35.5% | 100.0% | 100.0% | 100.0% | 100.0% | -80178.9% | 6.7% | -908.2% | -351.5% | -765.9% |
| Operating Margin | -6714.8% | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | -446.3% | -1026.1% |
| Net Profit Margin | -6046.2% | -6046.2% | -28720.7% | -5345.9% | -3460.4% | -9985.3% | -103960.6% | -4152.1% | -1116.8% | -447.8% | -1021.9% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -40.2% | -40.2% | -32.0% | -50.2% | -50.6% | -43.0% | -51.6% | -134.3% | — | — | — |
| ROA | -36.2% | -36.2% | -28.8% | -43.4% | -46.6% | -40.3% | -47.0% | -32.8% | -29.0% | -65.0% | -47.8% |
| ROIC | -37.8% | -37.8% | -30.8% | -40.6% | -59.8% | -75.4% | -69.3% | — | — | — | — |
| ROCE | -42.6% | -42.6% | -34.5% | -48.6% | -50.9% | -42.4% | -50.8% | -37.7% | -32.2% | -69.1% | -51.6% |
CRNX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $102M exceeds total debt of $49M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.04 | 0.10 | 0.01 | 0.01 | 0.02 | 0.05 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.05 | -0.16 | -0.01 | -0.09 | -0.60 | -0.53 | -0.30 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | -1143.63 | -546.18 |
Net cash position: cash ($102M) exceeds total debt ($49M)
CRNX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Crinetics Pharmaceuticals, Inc.'s current ratio of 12.32x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 13.07x to 12.32x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.32 | 12.32 | 23.04 | 13.07 | 12.45 | 21.55 | 16.92 | 14.79 | 21.03 | 16.91 | 13.89 |
| Quick Ratio | 12.30 | 12.30 | 23.04 | 13.07 | 12.45 | 21.55 | 16.92 | 14.79 | 21.03 | 16.75 | 13.78 |
| Cash Ratio | 12.08 | 12.08 | 22.69 | 12.71 | 12.06 | 20.86 | 16.29 | 14.20 | 20.68 | 15.82 | 13.65 |
| Asset Turnover | — | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.13 | 0.05 |
| Inventory Turnover | 2.46 | 2.46 | — | — | — | — | — | — | — | 65.48 | 52.04 |
| Days Sales Outstanding | — | 28.08 | 2975.51 | 850.51 | 186.85 | 687.00 | 9423.17 | 421.60 | — | 131.01 | 44.62 |
CRNX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Crinetics Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $94M | $81M | $58M | $52M | $38M | $30M | $24M | $12M | $14M | $14M |
Peer Comparison
Compare CRNX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CRNXYou | $5B | -8.8 | — | — | 35.5% | -6714.8% | -40.2% | -37.8% | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 CHRS | $213M | 1.2 | — | — | -37.3% | -429.5% | 275.4% | — | — |
 ACVA | $1B | -16.7 | — | 16.4 | 62.1% | -8.1% | -15.2% | -13.5% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 NVAX | $2B | 3.6 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 ESPR | $653M | -28.5 | 17.1 | — | 67.9% | 15.0% | — | 66.5% | 9.1 |
 XNCR | $903M | -9.9 | — | — | 91.6% | -141.4% | -14.0% | -16.3% | — |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
See CRNX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRNX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CRNX vs RCUS
Side-by-side business, growth, and profitability comparison vs Arcus Biosciences, Inc..
Start ComparisonCRNX — Frequently Asked Questions
Quick answers to the most common questions about buying CRNX stock.
What is Crinetics Pharmaceuticals, Inc.'s P/E ratio?
Crinetics Pharmaceuticals, Inc.'s current P/E ratio is -8.8x. This places it at the 50th percentile of its historical range.
What is Crinetics Pharmaceuticals, Inc.'s ROE?
Crinetics Pharmaceuticals, Inc.'s return on equity (ROE) is -40.2%. The historical average is -57.4%.
Is CRNX stock overvalued?
Based on historical data, Crinetics Pharmaceuticals, Inc. is trading at a P/E of -8.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Crinetics Pharmaceuticals, Inc.'s profit margins?
Crinetics Pharmaceuticals, Inc. has 35.5% gross margin and -6714.8% operating margin.